Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated with hypertrophic ...

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...

Stifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

However, Condulis cites a challenging path for the company to differentiate EDG-7500 from aficamten, a rival HCM candidate from Cytokinetics (CYTK). Meanwhile, despite recent positive trial data ...

A Maine coon cat named Mittens became an accidental jetsetter this month when her cage was overlooked in a plane cargo hold and she made three trips in 24 hours between New Zealand and Australia.

Other investigational procedures while participating in this study are not permitted. Since completion of a previous trial of aficamten has: Developed new-onset paroxysmal or permanent atrial ...

As experts continue monitoring and surveying the environment and the nation’s food supply for H5N1 bird flu, a rash of dead cats has many officials on edge. From pet cats in Los Angeles County ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...